HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
和黄医药（纳斯达克/伦敦证交所：HCM）是一家处于商业化阶段的创新型生物医药公司，致力于发现、全球开发和商业化治疗癌症和免疫性疾病的靶向药物和免疫疗法。和黃醫藥是一家處于商業化階段的創新型生物醫藥公司，致力于發現、全球開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法。
和黄医药（纳斯达克/伦敦证交所：HCM）是一家处于商业化阶段的创新型生物医药公司，致力于发现、全球开发和商业化治疗癌症和免疫性疾病的靶向药物和免疫疗法。和黃醫藥是一家處于商業化階段的創新型生物醫藥公司，致力于發現、全球開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法。
Location: China, Hong Kong, Hong Kong Island
Employees: 1001-5000
Total raised: $735M
Founded date: 2000
Investors 1
| Date | Name | Website |
| 16.07.2020 | General At... | generalatl... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.07.2021 | - | $535M | - |
| 08.04.2021 | - | $100M | - |
| 25.06.2020 | - | $100M | General At... |
Mentions in press and media 16
| Date | Title | Description |
| 13.07.2021 | HUTCHMED Limited Announces First Commercial Sale of ORPATHYS® in China, Triggering a USD 25 million Milestone Payment from AstraZeneca | HUTCHMED (China) Limited announced the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMEDs oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, which occurred on July 12, 2021. Th... |
| 13.07.2021 | AstraZeneca : HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca | HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMED’s or... |
| 18.06.2021 | HUTCHMED (CHINA) LIMITED Hutchmed (China) Seeks to Raise More Than US$600 Million in Hong Kong IPO | By P.R. Venkat Hutchmed (China) Ltd. is planning to raise more than US$600 million through a listing in Hong Kong, becoming the latest U.S.-listed Chinese company seeking to tap the Asian financial center's equity market. Hutchmed (China), ... |
| 09.04.2021 | HK-based buyout firm Baring to invest $100m in Chinese drug maker Hutchmed | Hong Kong-based buyout firm Baring Private Equity Asia has agreed to purchase $100 million worth of shares in Hutchison China MediTech (Hutchmed), a US- and London-listed, commercial-stage, biopharmaceutical firm that aims to treat cancer a... |
| 09.04.2021 | HK-based buyout firm Baring to invest $100m in Chinese drug maker Hutchmed | Premium Hong Kong-based buyout firm Baring Private Equity Asia has agreed to purchase $100 million worth of shares in Hutchison China MediTech (Hutchmed), a US- and London-listed, commercial-stage, biopharmaceutical firm that aims to treat ... |
| 08.04.2021 | HUTCHISON CHINA MEDITECH LIMITED HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J... |
| 09.12.2020 | With plans to bring surufatinib stateside, Chi-Med vastly scales up manufacturing with new Chinese plant | Hutchison China MediTech, or Chi-Med, is attempting to break new ground by bringing its internally developed oncology candidate surufatinib to US shores—which would make it just the second Chinese-developed drug to do... |
| 25.06.2020 | Chi-Med Announces US$100 Million Equity Investment by General Atlantic | Strategic investment demonstrates General Atlantic’s support of Chi-Med’s global ambitions Purchase price equivalent to US$25.00 per ADS, a 10.4% premium to the 30-day volume weighted average price (“VWAP”) |
| 25.06.2020 | Chi-Med Receives US$100M Equity Investment from General Atlantic | Hutchison China MediTech Limited (Nasdaq/AIM: HCM) sold US$100m of shares at a price equivalent to US$25.00 per American Depositary Share via a private placement to General Atlantic, a global growth equity firm. This fundraise could increas... |
| 01.06.2020 | AbbVie grabs SHP2 inhibitors from China's Jacobio; Chi-Med set on US filing of surufatinib | → AbbVie has found its next targeted cancer therapy in China, licensing a suite of SHP2 inhibitors from Beijing-based Jacobio. A key node on the RAS/MAP kinase pathway, SHP2 helps drive abnormal cell growth and plays a ro... |
Show more